###### Strengths and limitations of this study

-   To our knowledge, this is the first systematic review to assess the predictive accuracy of metabolomics for an adverse pregnancy outcome.

-   Using small for gestational age (SGA) as surrogate for fetal growth restriction---just as in epidemiological investigations---improves the translational potential of metabolomics.

-   Identification of techniques, types of maternal samples and chemical classes paves the way for future metabolomics investigations on fetal growth patterns.

-   Available data could not support a meta-analysis; further studies should include accuracy measures of individual metabolites or chemical subclasses in predicting SGA.

Introduction {#s1}
============

Fetal growth restriction (FGR) and small-for-gestational-age (SGA) infants are major concerns in modern obstetrics.[@R1] SGA is commonly used as a proxy for FGR,[@R4] despite the subtle differences between these two pathological conditions. The prevalence of both varies according to the criteria applied and on the population and setting, although it reaches as much as 25% in low-income and middle-income countries.[@R5] SGA newborns may have adverse health effects, such as stillbirth,[@R4] perinatal asphyxia,[@R6] impaired neurodevelopment[@R7] and increased cardiovascular risk.[@R8] To date, there are no robust prediction tools for SGA using clinical factors,[@R10] ultrasound data[@R12] or placental biomarkers.[@R14]

For hypothesis-generating or validation purposes, metabolomics is a novel area of biomarker, discovery, development and clinical diagnostics in translational medicine.[@R15] Metabolomics is the study of all metabolites[@R15] in a given sample, that is, low molecular weight compounds (50--2000 Da) that are intermediates of biochemical reactions and metabolic pathways, considered to directly reflect cellular activity and phenotype.[@R15] Recent studies have evaluated the pathophysiology[@R17] of SGA with metabolomics. However, little is known about the potential of metabolomics to identify predictive compounds of SGA.

Since metabolomics can identify multiple metabolites from low volume samples and create a model from a collection of these samples,[@R15] it is a promising technology for hypothesis generation in a heterogeneous condition such as SGA. The prediction of SGA in pregnancy would help refer women to specialised care facilities, improving maternal and neonatal outcomes.[@R21]

In this context, our review question was 'What is the accuracy of metabolomics for predicting FGR?'. The main objective of this systematic review was to assess the accuracy of metabolomics techniques in predicting SGA. As a secondary aim, we intended to determine which metabolites are predictive of this condition.

Methods {#s2}
=======

The protocol for this systematic review was published previously.[@R23] This study follows international guidelines for transparency (International Prospective Register of Systematic Reviews) and respects the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.[@R24]

Literature search strategy {#s2-1}
--------------------------

Two independent researchers (DFBL and A-CM) assessed 11 electronic databases (PubMed, EMBASE, Latin American and Caribbean Health Sciences Literature, Scientific Electronic Library Online, Health Technology Assessment, Database of Abstracts of Reviews of Effects, Aggressive Research Intelligence Facility, Cumulative Index of Nursing and Allied Health Literature, Maternity and Infant Care, Scopus, and Web of Science) and grey literature. There were no limits or language constraints; the search strategy covered published documents between 1998 and 2018. The keywords 'small for gestational age', 'metabolomics', 'prediction' and 'antenatal', and variations of each, were combined with Boolean operators depending on each database requirements. The full EMBASE literature search was as follows: ('fetal growth retardation' OR 'fetal growth restriction' OR 'intrauterine growth restriction' OR 'intrauterine growth retardation' OR 'small for gestational age') AND ('metabolomic\*' OR 'metabonomic\*' OR 'metabolit\* 'H NMR' OR 'proton NMR' OR 'proton nuclear magnetic resonance' OR 'liquid chromatogra\*' OR 'gas chromatogra\*' OR 'UPLC' OR 'ultra-performance' OR 'ultra performance liquid chromatograph\*') AND ('pregnan\*' OR 'antenat\*' OR 'ante nat\*' OR 'prenat\*' OR 'pre nat\*') AND ('screen\*' OR 'predict\*' OR 'metabolic profil\*'). Please check [online supplementary material 1](#SP1){ref-type="supplementary-material"} for more details.
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Outcomes and subgroup analysis {#s2-2}
------------------------------

The primary outcome was SGA, as a surrogate for FGR and defined as birth weight \<10th centile, by population-based or customised charts. The secondary outcomes were birth weight ≤5th or ≤3rd centile.

The intended subgroup analysis comprised the type of metabolomics technique applied (nuclear magnetic resonance, NMR; gas or liquid chromatography coupled with mass spectrometry, GC-MS or LC-MS, respectively); maternal health status before pregnancy (women with vs without any chronic health condition); type of SGA suspected during pregnancy (early vs late SGA); and type of pregnancy (singleton vs multiple pregnancy).

Selection criteria of studies, data collection and analysis {#s2-3}
-----------------------------------------------------------

Cohort or case--control studies were included if maternal samples were collected before the clinical diagnosis of SGA, if any metabolomics technique was applied and if the results of SGA were presented. Articles presenting data from the same research project but analysing distinct metabolites or showing data from different countries were included. Studies were excluded (1) according to study design; (2) if they had not applied any metabolomics technique; (3) if they were only experimental studies; (4) if it was not possible to extract data on SGA; or (5) if they presented duplicate data, in which case the most complete publication was included for final analysis.

Two researchers (DFBL and A-CM) independently selected studies, extracted data and discussed discrepancies. One additional reviewer (EFMJ or RTS) helped to decide, by majority, when no consensus was reached.

Piloted standardised forms were applied for data extraction, including pregnancy characteristics and experimental details. The Human Metabolome Database (HMDB)[@R25] and the Kyoto Encyclopedia of Genes and Genomes[@R26] were used for matching chemical class and metabolic pathways of each metabolite, respectively.

Risk of bias and assessment of concerns regarding applicability {#s2-4}
---------------------------------------------------------------

Two researchers (DFBL and A-CM) independently evaluated individual studies using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool.[@R27] One of the third reviewers (EFMJ or RTS) helped in decision-making when no consensus was achieved.

Each study was classified as high, low or unclear risk of bias in four domains (patient selection, index test, reference standard, and flow and timing), and as high, low or unclear concerns regarding applicability in the first three domains. We did not consider two signalling questions ('Was a case-control design avoided?' and 'Was there an appropriate interval between the index test and reference standard?'). The nested case--control design was an inclusion criterion, and maternal samples should have been collected during pregnancy, that is, before the SGA diagnosis. Studies were considered 'low risk', for example, (1) if pregnancy or neonatal complications were not excluded in just one group of participants or data on participant selection had been provided; (2) if methods for sample preparation and interpretation were standardised or metabolite threshold was defined before the experiments (for targeted analysis); (3) if the adequacy and reasons for choosing the reference birthweight chart had been explained; or (4) if large-for-gestational-age babies had been excluded from the final comparative analysis.

Data synthesis {#s2-5}
--------------

A quantitative summary of data was performed when any predictive accuracy measures could be extracted. Authors were contacted to provide additional information, when necessary. However, only Delplancke *et al*[@R28] replied. The estimation of likelihood ratios and hierarchical summary receiver operator characteristic curve[@R29] was planned, as well as assessment of heterogeneity and publication bias.[@R30] However, due to lack of data, a meta-analysis could not be performed.

Patient and public involvement {#s2-6}
------------------------------

There was no patient or public involvement in conducting this systematic review.

Results {#s3}
=======

Literature search characteristics {#s3-1}
---------------------------------

The literature search for this systematic review was performed in February 2018 and rerun in November 2018. A total of 9181 references were retrieved ([figure 1](#F1){ref-type="fig"}). After the removal of duplicate records (n=273), title and abstract screening, and analysis of the remaining 148 full-text articles, 15 articles were included.[@R17] See [online supplementary material 2](#SP2){ref-type="supplementary-material"} for the excluded studies.
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![PRISMA flow chart of study identification, screening and selection. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses. From Moher D, *et al*[@R24] For more information, visit [www.prisma-statement.org](www.prisma-statement.org).](bmjopen-2019-031238f01){#F1}

Characteristics of the included studies {#s3-2}
---------------------------------------

The characteristics of the included studies are shown in [table 1](#T1){ref-type="table"}. The prevalence of SGA ranged from 7.3%[@R33] to 21.5% in cohort studies.[@R28] There were no studies using birth weight ≤3rd centile to define SGA. The time interval between initial participant enrolment and publication varied from 3[@R17] to 54 years,[@R40] although these data were unclear in 38% of the reports.[@R18] In nested case--control studies, participants were matched by maternal age,[@R17] ethnicity,[@R17] parity,[@R38] body mass index[@R17] or infant gender.[@R18]

###### 

Main characteristics of included studies

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors, year                     Country, year of participants' enrolment            Study design           Affected/Non-affected   Gestational age at assessment      Type of pregnancy                                                        Parity                                                               Birthweight curve
  --------------------------------- --------------------------------------------------- ---------------------- ----------------------- ---------------------------------- ------------------------------------------------------------------------ -------------------------------------------------------------------- -------------------------
  Outcome: SGA \<5th centile                                                                                                                                                                                                                                                                                            

  Costet *et al*, 2012[@R31]        France, 2002--2006 (PELAGIE cohort)                 Nested case--control   134/399                 11 weeks                           Single pregnancy                                                         Nulliparous and parous women, unclear proportions                    Customised curve

  Ertl *et al*, 2012[@R32]          UK\*                                                Nested case--control   150/1000                11^+0^--13^+6^ weeks               Unclear                                                                  55.3% nulliparous in SGA group, 48.1% nulliparous in control group   Population-based charts

  Outcome: SGA \<10th centile                                                                                                                                                                                                                                                                                           

  Grandone *et al*, 2006[@R33]      Italy\*                                             Cohort                 31/393                  17.1±1.2 weeks†\                   Single pregnancy; no maternal pre-existing conditions                    Unclear                                                              Population-based charts
                                                                                                                                       (mean)                                                                                                                                                                           

  van Eijsden *et al*, 2008[@R39]   The Netherlands, 2003--2004\                        Cohort                 429/3275                13.5±3.3 weeks (mean)              Term deliveries, no diabetes or hypertension                             57.6% nulliparous                                                    Population-based charts
                                    (ABCD study)                                                                                                                                                                                                                                                                        

  Horgan *et al*, 2011[@R17]        Australia, 2008--2011\                              Nested case--control   40/40                   14--16 weeks                       Single pregnancy; no other pregnancy complications                       Nulliparous                                                          Customised curve
                                    (SCOPE cohort)                                                                                                                                                                                                                                                                      

  Gernand *et al*, 2013[@R40]       USA, 1959--1965 (Collaborative Perinatal Project)   Nested case--control   395/1751                ≤26 weeks                          Single pregnancy; term deliveries                                        Parous women                                                         Population-based charts

  Sulek *et al*, 2014[@R18]         Singapore\*\                                        Nested case--control   41/42                   26--28 weeks                       Single pregnancy; term deliveries; no maternal pre-existing conditions   Nulliparous and parous women, unclear proportions                    Population-based charts
                                    (GUSTO study)                                                                                                                                                                                                                                                                       

  Choi *et al*, 2016[@R34]          South Korea, 2012--2013                             Cohort                 39/217                  First, second or third trimester   Single pregnancies                                                       Nulliparous and parous women, unclear proportions                    Population-based charts

  Kiely *et al*, 2016[@R35]         Ireland, 2008--2011\                                Cohort                 190/1578                14--16 weeks                       Single pregnancy; no maternal pre-existing conditions                    Nulliparous                                                          Customised curve
                                    (SCOPE cohort)                                                                                                                                                                                                                                                                      

  Ong *et al*, 2016[@R37]           Singapore\*\                                        Cohort                 83/827                  26--28 weeks                       Single pregnancy; no maternal chronic illness                            43.5% nulliparous                                                    Population-based charts
                                    (GUSTO study)                                                                                                                                                                                                                                                                       

  Wang *et al*, 2016[@R36]          Taiwan, 2000--2001\                                 Cohort                 35/188                  Third trimester                    Unclear; term deliveries                                                 48% nulliparous                                                      Population-based charts
                                    (Taiwan Maternal and Infant Cohort Study)                                                                                                                                                                                                                                           

  Delplancke *et al*, 2018[@R28]    New Zealand\*                                       Cohort                 20/73                   34--37 weeks                       Unclear; term deliveries                                                 Unclear                                                              Customised curve

  Luthra *et al*, 2018[@R38]        USA, 2010--2012 (TIDES study)                       Nested case--control   53/106                  First and second trimester         Single pregnancies; term deliveries                                      60% nulliparous                                                      Customised curve

  Gong *et al*,\                    UK, 2008--2012 (POP study)                          Nested case--control   162/259                 36 weeks                           Single pregnancies; term deliveries                                      Nulliparous                                                          Customised curve
  2018[@R41]                                                                                                                                                                                                                                                                                                            

  Morillon *et al*, 2018[@R42]      2008--2011 (SCOPE study)                            Nested case--control   40/40                   20 weeks                           Single pregnancies                                                       Nulliparous                                                          Customised curve
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Unclear period of participant recruitment.

†Mean for all study participants.

ABCD, Adolescent Brain Cognitive Development; GUSTO, Growing Up in Singapore Towards healthy Outcomes; PELAGIE, Étude Longitudinale sur les Anomalies de la Grossesse, l'Infertilité et l'Enfance; POP, Pregnancy Outcome Prediction; SCOPE, Screening of Pregnancy Endpoints; SGA, small for gestational age; TIDES, Tackling Inequalities and Discrimination Experiences in health Services.

Participant characteristics varied between studies. Regarding gestational age at assessment, samples were collected in the second trimester in half of the studies.[@R17] In three reports, women were assessed at least twice.[@R34] In one study, maternal blood was drawn either in the first or second trimester,[@R40] and in another three studies only samples from the third trimester were considered.[@R28] In the latter case, maternal hair was divided according to length, allowing evaluation of second-trimester and third-trimester metabolites.[@R28] Studies considering the fifth centile as the cut-off sampled women in the first trimester.[@R31] Twin pregnancy was a clear exclusion criterion in most studies.[@R17] Pregnancy aided by assisted reproduction[@R18] or women with pre-existing conditions[@R17] were also excluded, although these data were incompletely reported.[@R28] When both nulliparous and multiparous women were enrolled, there was no data analysis according to parity. Half of the studies considered term deliveries exclusively,[@R18] and the remaining studies did not differentiate results according to gestational age at birth.

Regarding clinical risk factors for SGA, only one paper mentioned a history of SGA, but findings were not adjusted for this variable.[@R32] All studies, except one,[@R28] cited participants' smoking status. The rate of smoking habit ranged from 2.4%[@R18] to 47.5%.[@R40] It is important to note that Gernand *et al*[@R40] analysed samples from women recruited between 1959 and 1965, when smoking while pregnant was encouraged, which explains the high rate of smoking participants. The duration of smoking or any differences in birth weight (absolute measures or centiles) were not clearly stated. Although more prevalent in SGA pregnancies, the results did not change with this variable control.[@R31] Only Gong *et al*[@R41] mentioned the suspicion of SGA in pregnancy, exhibiting decreasing abdominal circumference growth velocity between 20 and 36 weeks. However, on final analysis, these babies were grouped with infants not suspected during pregnancy.

Subgroup analysis {#s3-3}
-----------------

Due to unavailable data, the only subgroup analysis performed was related to the metabolomics approach applied ([table 2](#T2){ref-type="table"}). There was no mention of adherence to metabolomics reporting data guidelines. LC-MS was the leading technique used. Three studies have investigated metabolites related to environmental exposure, from contaminated water,[@R31] consumer products[@R36] or pesticides,[@R42] while others have analysed endogenous compounds.[@R32] Only Luthra *et al*[@R38] conducted a biomarker validation study, while Gong *et al*[@R41] chose to analyse the top 10 statistically different metabolites according to infant sex.

###### 

Subgroup analysis of included studies according to which metabolomics technique was applied

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors, year                                        Metabolomics technique                                                                                                         Maternal sample/storage temperature   Prediction model\*               Targeted compounds                                      Coefficient of variation/limits of quantitation                             Predictive compounds                                                                                        Sensitivity\   AUC
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             /Specificity   
  ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ------------------------------------- -------------------------------- ------------------------------------------------------- --------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- -------------- -------
  Nuclear magnetic resonance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Luthra *et al*, 2018[@R38]                           ^1^H-NMR 1D NOESY with presaturation and homonuclear 2D *J*-resolved at 300 K Bruker 600 MHz Advance III HD spectrometer       Urine/−80°C                           Targeted                         Tyrosine, acetate, formate, trimethylamine              NA                                                                          None                                                                                                                       

  Gas chromatography coupled to mass spectrometry                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Costet *et al*, 2012[@R31]                           GC-MS\                                                                                                                         Urine/−20°C                           Targeted                         Trichloroacetic acid                                    \<5%/0.01 mg/L                                                              None                                                                                                        0.1/0.93       
                                                       Simple headspace SPME-capillary GC                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Sulek *et al*, 2014[@R18]                            GC-MS\                                                                                                                         Hair/−20°C                            Untargeted                       NA                                                      NA                                                                          ↓ Lactate\                                                                                                                 0.998
                                                       Thermo Trace GC Ultra system coupled to ISQ mass selective detector\                                                                                                                                                                                                                                                                      ↓ Levulinate\                                                                                                              
                                                       Capillary GC column: Phenomenex ZB-1701 (30 m × 250 µm id × 0.15 µm with 5 m guard column)                                                                                                                                                                                                                                                ↑2-methyloctadecanoate\                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                 ↑Tyrosine\                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                 ↓ Margarate                                                                                                                

  Delplancke *et al*, 2018[@R28]                       GC-MS\                                                                                                                         Hair/−20°C                            Untargeted                       NA                                                      NA                                                                          ↑ Margaric acid\                                                                                                           0.72\
                                                       Agilent 7890B gas chromatograph, capillary column\                                                                                                                                                                                                                                                                                        ↑ Pentadecanoic acid\                                                                                                      0.73\
                                                       ZB-1701 (30 m × 250 µm id × 0.15 µm with 5 m guard column)\                                                                                                                                                                                                                                                                               ↑ Myristic acid‡                                                                                                           0.73
                                                       5977A mass spectrometer, electron impact ionisation                                                                                                                                                                                                                                                                                                                                                                                                                  

  Liquid chromatography coupled to mass spectrometry                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Grandone *et al*, 2006[@R33]                         LC-MS/MS triple quadrupole Applera API 3000, TurboIonSpray ionisation                                                          Amniotic fluid/−80°C                  Targeted                         Homocysteine                                            Unclear                                                                     ↑Homocysteine (1.29 µM; 1.05--1.51 µM)                                                                                     

  Horgan *et al*, 2011[@R17]                           UPLC-MS/MS\                                                                                                                    Plasma/−80°C                          Untargeted                       NA                                                      NA                                                                          Hexacosanedioic acid, diglyceride, lyso-phosphocholine, sphinganine 1-phosphate, sphingosine 1-phosphate§                  0.90
                                                       Thermo Fisher LTQ Orbitrap, ESI                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Ertl *et al*, 2012[@R32]                             HPLC-MS/MS\                                                                                                                    Serum/−80°C                           Targeted                         25(OH)D~2~; 25(OH)D~3~                                  6.3%\*, 6.6%† (D~2~); 6.5%\*, 7.3%† (D~3~)/unclear                          ↓25,OH,vitamin D (12.16 ng/mL; 8.09--20.54 ng/mL)                                                           0.72/0.45      
                                                       Shimadzu Prominence HPLC system with a column Phenomenex Luna C8 3×50 mm;\                                                                                                                                                                                                                                                                                                                                                                                           
                                                       AbSciex API-5000 triple quadrupole, ESI                                                                                                                                                                                                                                                                                                                                                                                                                              

  Gernand *et al*, 2013[@R40]                          LC-MS/MS                                                                                                                       Serum/−20°C                           Targeted                         25(OH)D~2~; 25(OH)D~3~                                  8.2%\* (D~2~) 5.9%\* (D~3~)/\<1 ng/mL                                       None                                                                                                        0.39/0.66      

  Choi *et al*, 2016[@R34]                             HPLC-MS/MS\                                                                                                                    Serum/−20°C                           Targeted                         Methylmalonic acid; homocysteine                        \<10%\*; \<10%†/unclear                                                     None                                                                                                                       
                                                       Waters HPLC system,\                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                       Applied Biosystems API-4000 MS/MS mass spectrometer                                                                                                                                                                                                                                                                                                                                                                                                                  

  Kiely *et al*, 2016[@R35]                            UPLC-MS/MS\                                                                                                                    Serum/−80°C                           Targeted                         25(OH)D~2~; 25(OH)D~3~; 3-epi-25(OH)D~3~                \<6%\*; \<5%†/0.57 ng/mL (D~2~); 0.26 ng/mL (D~3~), 0.41 ng/mL (epi-D~3~)   None                                                                                                                       
                                                       Waters Acquity UPLC system,\                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                       Waters Triple Quadrupole TQD mass spectrometer                                                                                                                                                                                                                                                                                                                                                                                                                       

  Ong *et al*, 2016[@R37]                              LC-MS/MS\                                                                                                                      Plasma/unclear                        Targeted                         25(OH)D~2~; 25(OH)D~3~                                  ≤10.3%\*,†/\<1.6 ng/mL                                                      None                                                                                                        0.12/0.87      
                                                       Applied Biosystems\                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                       Thermo Hypersil BDS C8 reverse-phase column                                                                                                                                                                                                                                                                                                                                                                                                                          

  Wang *et al*, 2016[@R36]                             LC-MS\                                                                                                                         Serum/unclear                         Targeted                         PFOA; long-chain PFCA                                   0.83--7.94%\*; 1.57--24.7%†/0.07--0.45 ng/mL¶                               PFDeA (OR 3.14; 95% CI 1.07 to 9.19), PFUnDA (OR 1.83; 95% CI 1.01 to 3.32)\*\*                                            
                                                       Agilent HPLC system,\                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                       Applied Biosystems Sciex API-4000 triple quadrupole mass spectrometer                                                                                                                                                                                                                                                                                                                                                                                                

  Gong *et al*,\                                       LC-MS/MS\                                                                                                                      Serum/unclear                         Untargeted                       NA                                                                                                                                  ↑N1,N12-diacetylspermine\*\*                                                                                               
  2018[@R41]                                           Shimadzu UK Limited UPLC system, ACE Excel 2 C18-PFP LC-column, Thermo Fisher Scientific Exactive Orbitrap mass spectrometer                                                                                                                                                                                                                                                                                                                                         

  Morillon *et al*, 2018[@R42]                         UPLC-MS/MS\                                                                                                                    Urine/−80°C                           Untargeted                       NA                                                                                                                                  None                                                                                                                       
                                                       Waters Acquity UPLC system,\                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                       Waters Synapt G2-S mass spectrometer                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Others                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  van Eijsden *et al*, 2008[@R39]                      GC-FID\                                                                                                                        Plasma/−80°C                          Semitargeted, lipid extraction   Elaidic, linoleic, alfa-linolenic, eicosatetraenoic,\   ≤2%--22%†/unclear                                                           ↓ Eicosatetraenoic acid (OR 1.5; 95% CI 1.07 to 2.11),\                                                                    
                                                       Solid phase extraction SPE, capillary GC                                                                                                                                                              EPA, DPA, DHA\                                                                                                                      ↓DPA (OR 1.49; 95% CI 1.06 to 2.1)                                                                                         
                                                                                                                                                                                                                                                             DGLA, AA, adrenic, and Osbond acids                                                                                                                                                                                                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Intra-assay coefficients of variation.

†Interassay coefficients of variation.

‡These metabolites were found in second-trimester hair segments.

§And more 14 metabolites that could not be identified certain based on chromatographic peak and mass: phenylacetylglutamine or formyl-N-acetyl-5-methroxykynurenamine; leucyl-leucyl-norleucine or sphingosine 1-phosphate; cervonyl carnitine and/or 1-alpha,25-dihydroxy-18-oxocholecalciferol; (15Z)-tetracosenoic acid or 10,13-dimethyl-11-docosyne-10,13-diol or *trans*-selacholeic acid; pencosenoic acid or cyclohexyl acetate or octanoic acid or methyl-heptenoic acid or 4-hydroxy-2-octenal or DL-2-aminooctanoic acid or 3-amino-octanoic acid; hydroxybutyrate or hydroxy-methylpropanoate or methyl methoxyacetate; lysophosphocoline and phosphocoline (more than 10 hits); phosphocoline (more than 20 hits); phosphocoline or ubiquinone-8; acetylleucil-leucil-norleucinal or oleoylglycerone phosphate or LPA(0:0/18:2(9Z,12Z)) or 1-16:1lysoPE or phosphocoline(O-11:1(10E)/2:0) or (3 s)−3,4-Di-N-hexanoyloxybutyl-1-phosphocoline or N-(3-hydroxy-propyl) arachidonoyl amine or N-methyl N-(2-hydroxy-ethyl) arachidonoyl amine or similar; lysophosphocholine (16:1) or cervonyl carnitine; preganediol-3-glucuronide or 3-alpha,20-alpha-dihydroxy-5-beta-pregnane-3-glucuronide; 6-hydroxyshingosine or (4OH,8Z,t18:1) sphingosine or 15-methyl-15-prostaglandin D2 or 15-R-prostaglandin E2 methyl ester.

¶Values for all studied metabolites.

\*\*Predictive compounds only for female babies.

AA, arachidonic acid;AUC, area under the receiver operating characteristic curve; DGLA, dihomo-gamma-linolenic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; ESI, electrospray ionisation; FID, flame ionisation detection; GC-MS, gas chromatography coupled to mass spectrometry;^1^H-NMR, hydrogen nuclear magnetic resonance; HPLC, high performance liquid chromatography; LC-MS, liquid chromatography coupled to mass spectrometry; NA, not applicable; NOESY, nuclear Overhauser effect spectroscopy; PFCA, perfluorocarboxylic acid; PFDeA, perfluorodecanoic acid; PFOA, perfluorooctanoic acid; PFUnDA, perfluoroundecanoic acid; SPME, solid phase microextraction; UPLC, ultra-performance liquid chromatography.

Maternal blood was the most common biological sample analysed by LC-MS in all studies,[@R17] except for one which used GC-MS.[@R39] Maternal urine was analysed by NMR,[@R38] GC-MS[@R36] or LC-MS.[@R42] There was only one report using amniotic fluid[@R33] and two using maternal hair,[@R18] all applying GC-MS. The period of laboratory analysis was rarely specified, which made it impossible to estimate the total time of sample storage.

Untargeted studies reported diverse metabolic features. Authors matched the peaks with an inhouse library[@R18] or HMDB-related database.[@R17] Horgan *et al*[@R17] found 785 compounds both in maternal and newborn samples; their predictive model included 19 metabolites (only 5 could be putatively identified; [table 2](#T2){ref-type="table"}) and used second-trimester maternal blood. Sulek *et al*[@R18] and Delplancke *et al*[@R28] prepared and analysed samples with GC-MS using similar protocols. Sulek *et al*[@R18] identified 32 statistically different chromatographic features from which they built a predictive model using five metabolites, including two fatty acids (2-methyloctadecanoate and margarate). In contrast, Delplancke *et al*[@R28] identified 198 metabolites, including three fatty acids (margaric, pentadecanoic and myristic acid) showing significantly higher levels in SGA cases, when second-trimester maternal hair segments were studied.

Analysis of identified metabolites {#s3-4}
----------------------------------

The identified compounds refer to 11 HMDB chemical classes. Fatty acids[@R18] comprised the most prevalent chemical class, followed by amino acids[@R18] and phosphosphingolipids[@R17] ([table 3](#T3){ref-type="table"}).

###### 

Predictive metabolites summarised according to their chemical class, subclass and biological process

  Predictive metabolites    Chemical class                       Chemical subclass                     Metabolic pathway
  ------------------------- ------------------------------------ ------------------------------------- -----------------------------------------------------------------------------------------------------------------------------
  Margarate                 Fatty acyls                          Fatty acids and conjugates            Lipid transport, metabolism, peroxidation
  Pentadecanoic acid        Fatty acyls                          Fatty acids and conjugates            Lipid transport, metabolism, peroxidation; fatty acid metabolism and biosynthesis
  Myristic acid             Fatty acyls                          Fatty acids and conjugates            Lipid transport, metabolism, peroxidation; fatty acid metabolism and biosynthesis
  Eicosatetraenoic acid     Fatty acyls                          Fatty acids and conjugates            Lipid transport, metabolism, peroxidation; lipid metabolism pathway
  Docosapentaenoic acid     Fatty acyls                          Fatty acids and conjugates            Lipid transport and metabolism, fatty acid metabolism, alpha linolenic acid and linoleic acid metabolisms
  Tyrosine\*                Carboxylic acids and derivatives     Amino acids, peptides and analogues   Catecholamine biosynthesis, phenylalanine and tyrosine metabolism, thyroid hormone synthesis, transcription and translation
  Homocysteine              Carboxylic acids and derivatives     Amino acids, peptides and analogues   Glycine and serine metabolism, methionine metabolism
  Hexacosanedioic acid      Carboxylic acids and derivatives     Dicarboxylic acid and derivatives     Fatty acid biosynthesis
  Sphinganine 1-phosphate   Sphingolipids                        Phosphosphingolipids                  Sphingolipid signalling pathway, neuroactive ligand-receptor interaction
  Sphingosine 1-phosphate   Sphingolipids                        Phosphosphingolipids                  Lipid metabolism pathway, sphingolipid metabolism
  PFDeA                     Alkyl halides                        Alkyl fluorides                       Not reported†
  PFUnDA                    Alkyl halides                        Alkyl fluorides                       Not reported†
  25,OH,vitamin D           Steroids and steroids derivatives    Vitamin D and derivatives             Lipid metabolism pathway
  Diglyceride               Glycerolipids                        Diradylglycerols                      Adipocytokine signalling pathway
  Lactate                   Hydroxy acids and derivatives        Alpha hydroxy acids and derivatives   Gluconeogenesis, glycogenosis types IB and IC, pyruvate metabolism, triosephosphate isomerase
  N1,N12-diacetylspermine   Carboximidic acids and derivatives   Carboximidic acids                     
  Lyso-phosphocholine       Glycerophospholipids                 Glycerophosphocholines                Not reported†
  2-methyloctadecanoate     Saturated hydrocarbons               Alkanes                               Not reported†
  Levulinate                Keto acids and derivatives           Gamma-keto acids and derivatives      Not reported†

\*Essential amino acid for infants.

†No human metabolic pathways reported at KEGG.

KEGG, Kyoto Encyclopedia of Genes and Genomes; PFDeA, perfluorodecanoic acid; PFUnDA, perfluoroundecanoic acid.

A total of 5974 women were assessed for vitamin D status. The results were presented as total vitamin D,[@R32] although vitamin D~2~, D~3~ or 3-epi-25(OH)D~3~ [@R35] metabolites were measured. The results were stratified according to season of maternal sampling or latitude. Either \<15 ng/mL (\<37.5 nmol/L)[@R40] or \<20 ng/mL (\<50 nmol/L)[@R32] levels characterised vitamin D deficiency, but were statistically different in SGA pregnancies only in the first trimester.[@R32] Horgan *et al*[@R17] found a metabolite that could represent a vitamin D derivative, but it was only predictive in combination with 18 other compounds; this model had an area under the curve (AUC) of 0.90 (optimal OR, 44; 95% CI 9 to 214).[@R17]

The second most frequent targeted metabolite was homocysteine,[@R33] although levels were only differentiated between normal and SGA pregnancies when measured in second-trimester amniotic fluid, with a multiple linear regression model of r^2^=0.012 and p=0.029.[@R33] Comparatively, the only common metabolite in the second-trimester maternal hair was margarate, with conflicting results since it was found to be either increased (AUC 0.72, 95% CI 0.58 to 0.86)[@R28] or decreased.[@R18] The N1,N12-diacetylspermine and the perfluorocarboxylic acids were associated with female SGA babies, not males. The former presented a fivefold decreased risk of SGA across quintiles. The perfluorodecanoic and perfluoroundecanoic acids presented OR of 3.14 (95% CI 1.07 to 9.19) and 1.83 (95% CI 1.01 to 3.32).[@R36] Tyrosine, an essential amino acid for infants, was part of the predictive model of maternal hair, combining five metabolites with an AUC of 0.998 (95% CI 0.992 to 1.0).[@R18] However, tyrosine did not predict SGA when urine samples were studied.[@R38] Methylmalonic acid,[@R34] acetate, formate or trimethylamine[@R38] did not differentiate SGA when compared with uncomplicated pregnancies (p\>0.05).

Risk of bias and applicability concerns {#s3-5}
---------------------------------------

[Figure 2](#F2){ref-type="fig"} shows synthesised data for all included studies. See [online supplementary material 3](#SP3){ref-type="supplementary-material"} for individual QUADAS-2 data.
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Regarding the risk of bias, all cohort studies conducted a consecutive participant inclusion.[@R28] Nested case--controls matched cases and controls randomly[@R33] or according to maternal and infant characteristics.[@R17] One study[@R41] failed to mention matching procedures ('Patient Selection' domain). Researchers were not blinded to SGA status when interpreting metabolomics results,[@R17] and thresholds of targeted metabolites were not prespecified[@R31] ('Index Test' domain). Conversely, SGA identification was not influenced by the metabolomics test, although it was unclear when laboratory experiments were performed in some studies.[@R18] Birthweight charts were adequate, except for two studies. The first did not report which centile was chosen,[@R18] and the second used a centile designed for a different population[@R33] ('Reference Test' domain). Two studies were ranked as 'high risk' because not all participants were included in the analysis[@R31] ('Flow and Timing' domain).

The QUADAS-2 tool also highlights the importance of how the findings of the included studies are suitable to the review question. In the patient selection domain, it was ranked as 'high applicability concerns' when infants born between the 4th and the 10th centile, but with normal abdominal circumference growth velocity, were not included in the final analysis.[@R41] It was 'unclear' when the gestational age of maternal assessment was not standardised,[@R34] or was inferred by hair segment length,[@R28] or when few metabolites from untargeted studies were chosen for interpretation[@R41] ('Index Test' domain). Finally, it was 'high' when the birthweight charts applied did not correspond to the study population[@R18] ('Reference Standard' domain).

Meta-analysis {#s3-6}
-------------

From the 15 included studies, only 3 were designed for prediction purposes[@R17] and provided the AUC. The remaining reports described statistical differences of metabolites between SGA pregnancies and controls.[@R28] Accuracy measures were extracted when available ([table 2](#T2){ref-type="table"}). However, due to marked heterogeneity ([tables 1 and 2](#T1 T2){ref-type="table"}) of gestational age at sampling, type of samples used, type of birthweight chart chosen, thresholds for vitamin D deficiency, metabolomics approach and identified compounds, a meta-analysis could not be performed.

Discussion {#s4}
==========

Main findings {#s4-1}
-------------

In this first systematic review of metabolomics and adverse pregnancy endpoints, we presented techniques and metabolites which were studied for the prediction of SGA. Any effect on birth weight has important implications for perinatal research, since it is related to short-term and long-term outcomes,[@R43] and in different generations.[@R47] Intrauterine environment influences fetal growth through epigenetic processes: altered gene expression potentially leads to distinct phenotypes.[@R49] Metabolomics is the most adequate approach to study this outcome since it is most directly related to phenotype.[@R50]

Interpretation of metabolomics findings in pregnancy can be challenging. First, maternal metabolite concentrations are influenced by placental transfer to and from the fetus. The 'mirror effect', seen for maternal plasma and venous cord blood metabolites at birth,[@R51] cannot be ruled out when only maternal specimens are studied. Second, maternal exposure to distinct compounds may affect metabolite levels. Statistically significant differences between SGA infants and controls may not express the totality of underlying pathological pathways and have no clinical meaning. Finally, it is unclear when the processes leading to SGA are initiated. The disruption in maternal metabolism can theoretically occur at any time. In general the lower the gestational age at which the condition is suspected, the more severe the phenotype will be at birth.[@R52] Thus, the description of clinical data in translational studies must deal with all these confounding factors.

Gestational age at sampling is probably the most important parameter for prediction purposes. With timely prediction, women could be referred to specialised care and have increased surveillance, and this in turn may lead to a reduction in perinatal mortality. There are temporal changes in the maternal metabolome during pregnancy[@R28]; therefore, it is reasonable to expect distinctive metabolites at different stages of pregnancy, as reported here. Unfortunately, a wide or unclear definition of gestational age of sampling[@R34] renders a more precise interpretation impossible and may limit the clinical application of these results.

In contrast, gestational age at birth and birthweight centile seem to be the hallmarks of severity and prognosis of growth restriction.[@R6] Indeed, term and preterm SGA babies show distinct clinical phenotypes, and there are concerns that some babies \<10th centile of birth weight are constitutionally small infants.[@R59] If only term deliveries are evaluated, the most severe cases of growth restriction may be potentially missed. Moreover, when term and preterm births are analysed together, or when lower cut-offs are not specified (eg, ≤3rd or ≤5th centile), the lack of predictive metabolites might mean that they are distinct conditions. Thus, we hypothesise that the predictive performance of metabolomics may be improved if data are analysed by gestational age at delivery and by different cut-offs of birthweight centiles.

Evidence suggests that tobacco smoke has an impact on birth weight,[@R62] although it is uncertain how and when fetal growth is impaired. It is possibly related to oxidative stress,[@R65] and both maternal and fetal metabolism may be disturbed at delivery.[@R66] Studies that were included did not investigate cigarette-related chemicals or quantify exposure to tobacco smoke. Therefore, no relationship between SGA and tobacco was found. Hence, we suggest that tobacco interferes with ongoing metabolic pathological processes, or its disturbance is related to additional metabolic pathways other than the one examined by the included studies.

Subgroup and metabolite findings {#s4-2}
--------------------------------

No reports have explored data on any maternal chronic condition, suspicion of SGA in pregnancy or number of fetuses. The lack of clear statements about participant selection has hindered data interpretation and precluded these analyses.

The majority of included studies performed a targeted approach, that is, a hypothesis-testing evaluation,[@R16] driven by epidemiological or experimental data regarding SGA newborns. None of the targeted metabolites[@R31] were in common with those found by 'hypothesis-generating' metabolic profiling[@R17] investigations. This reinforces the suggestion that various maternal metabolic pathways may be triggered by the SGA condition and be detected by different biological samples. However, since blood is a very complex sample and GC-MS only evaluates volatile molecules,[@R50] our findings may be biased by study methodologies.

Untargeted studies, as expected, have characterised several metabolites that may be validated in future investigations. Nine lipids and fatty acid metabolites,[@R17] two amino acids[@R18] and a steroid[@R17] have been identified as potential biomarkers of SGA.

All lipid-related metabolites identified are intermediates for energy storage and breakdown. Most metabolites were found in maternal blood[@R17] or hair of the SGA group.[@R18] Blood levels of saturated and monounsaturated non-esterified fatty acids apparently remain stable throughout pregnancy, while long-chain polyunsaturated fatty acid (docosahexaenoic acid and eicosapentaenoic acid, for example) measurements seem to show ethnicity-related changes.[@R57] Experimental data show the importance of hypoxia and oxidative stress to placental function, and ultimately to birth weight.[@R68] Findings from included studies may represent a dysregulation of lipid pathways at the placental level, but an association with maternal background is unclear. Therefore, we hypothesise that disorders of lipid metabolism may be the 'metabolic snapshot' of defective deep placentation[@R70] and might reflect maternal efforts to respond to impaired fetal growth.

Recommendations on the assessment of vitamin D and cut-offs to define vitamin D deficiency in pregnancy are controversial.[@R71] However, vitamin D supplementation decreases SGA risk.[@R72] In early pregnancy, vitamin D status has been related to SGA,[@R73] which is in accordance with this review, despite the inconsistent findings.[@R75] There is evidence that trophoblasts actively produce and secrete vitamin D metabolites,[@R76] but it is not clear how they mediate fetal growth impairment. Altered hepatic gene expression and liver function in vitamin D-deficient female rats[@R77] and single nucleotide polymorphisms[@R78] in vitamin D receptor gene have been suggested as mechanisms to be explored by a multidimensional omics approach.

Finally, homocysteine is an intermediate metabolite of the folate cycle. It is indirectly involved with DNA methylation and is a marker of folate deficiency.[@R79] Maternal levels rarely reach hyperhomocysteinaemia limits,[@R80] but folate depletion[@R81] and homocysteine itself[@R80] are thought to be associated with a higher SGA risk. In this review, homocysteine was only statistically different in SGA pregnancies when measured in amniotic fluid,[@R33] although within the normal ranges proposed for 17--21 weeks.[@R84] Since amniocentesis is generally performed in women at higher obstetrical risk, future studies should investigate whether homocysteine in amniotic fluid represents a confounding factor or a new biomarker.[@R85]

Methodological quality {#s4-3}
----------------------

Most studies were ranked as 'low risk' of bias or applicability to the review question. However, the lack of clear descriptions of laboratory experiments, including sample preparation and storage, and blinding of the researchers to the case/control status are major pitfalls of the included studies.

Strengths and limitations {#s4-4}
-------------------------

To our knowledge, this is the first systematic review of metabolomics and an adverse pregnancy outcome (SGA). We presented possible biomarkers of SGA pathophysiology, metabolites implicated in lipid transport and metabolic pathways, as well as gluconeogenesis.

However, this analysis has some limitations. First, included studies showed heterogeneity, which is fundamental in systematic reviews. Indeed, there was a wide variety of participant characteristics and methods used, and not all authors provided a detailed description of methods employed. Although the Metabolomics Standards Initiative was released in 2007,[@R86] there is still poor adherence to guidelines.[@R87] Clear reporting[@R15] and data sharing in repositories are crucial steps in identifying features of interest, specifically possible biomarkers to be validated in the clinical studies.[@R15] Second, we could not perform a meta-analysis of the extracted data, impacting the translational potential of metabolomics.

Third, we considered that birth weight was a surrogate measure of intrauterine development. SGA and FGR are not interchangeable concepts. However, SGA has been used as a surrogate for FGR in many clinical studies due to difficulties in defining optimal intrauterine growth: (1) FGR diagnosis relies mostly on ultrasound measurements of fetal biometry,[@R3] which in turn is subject to systematic errors[@R90]; (2) intrauterine development is adaptive, rather than uniform[@R91] or only genetically driven[@R49]; and (3) growth impairment at birth better identifies adverse neonatal outcomes than during pregnancy.[@R58] It is recognised that changes in obstetric care occur when growth restriction is suspected, and neonatal outcomes are improved.[@R21] Thus, an accurate prediction of SGA during pregnancy will be a turning point in modern obstetrics.

Conclusions and implications for practice {#s5}
=========================================

Using the available clinical tools, efforts to predict SGA remain disappointing. Since SGA is a heterogeneous condition, it benefits from metabolomics. This novel area of research allows analysis of numerous types of biological fluids and detects thousands of metabolites in complex samples.[@R15] However, findings of this systematic review must be interpreted with caution. The type of samples used may have influenced LC-MS (second-trimester maternal blood) and GC-MS (second-trimester maternal hair) findings in individual studies. Furthermore, the prediction of SGA in the context of maternal disorders, suspected FGR and twin pregnancies is an open field for future metabolomics studies, and environmental exposure investigation as well.

Surprisingly, none of the studies used ≤3rd centile of birth weight as a cut-off or analysed preterm deliveries and hypertensive syndromes. Considering our findings and the different phenotypic manifestations of SGA, we envision a better performance when (1) cut-offs other than the 10th centile are tested; (2) data on gestational age at sampling and at birth are standardised; and (3) other pregnancy-related syndromes are considered, especially hypertension. Thus, future metabolomics results should advance in these critical points.

Finally, all detected biomarkers were related to lipid pathways and energy metabolism. We consider that research efforts to predict SGA should focus on compounds involved in these pathways, up to the second trimester of pregnancy.
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